The Anterior Gradient-2 pathway as a model for developing peptide-aptamer anti-cancer drug leads that stimulate p53 function

Current Chemical Biology

Volumn 3, Issue 2, 2009, Pages 124-137

  Fourtouna, Argyro ^a   Murray, Euan ^a   Nicholson, Judith ^a   Maslon, Magdalena M ^a   Pang, Lisa Y ^a   Dryden, David T F ^b   Hupp, Ted R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b School of Chemistry Joseph Black Building   (United Kingdom)

Author keywords

Anterior Gradient 2; Aptamers; Cancer; p53; Therapeutics

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; ANTINEOPLASTIC AGENT; PEPTIDE APTAMER; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; CELL FRACTIONATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; REGULATORY MECHANISM; REVIEW;

EID: 68449083815     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231309788166442     Document Type: Review

References (61)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-83.
3. Dey A, Verma C, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008; 98: 4-8.
4. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ 2006; 13: 1027-33.
5. Hupp TR, Walkinshaw M. Multienzyme assembly of a p53 transcription complex. Nat Struct Mol Biol 2007; 14: 885-87.
6. Arva NC, Gopen TR, Talbott KE, et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005; 280: 26776-87.
7. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
8. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7: 860-9.
9. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2: 202-6.
10. Diamandis P, Wildenhain J, Clarke ID, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol 2007; 3: 268-73.
11. Hillenmeyer ME, Fung E, Wildenhain J, et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 2008; 320: 362-5.
12. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454-63.
13. Godar S, Ince TA, Bell GW, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134: 62-73.
14. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-90.
15. Leedham SJ, Preston SL, McDonald SA, et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008; 57: 1041-48.
16. Hupp TR. Development of physiological models to study stress protein responses. Methods Mol Biol 2000; 99: 465-83.
17. Darragh J, Hunter M, Pohler E, et al. The Calcium Binding Domain of SEP53 is required for survival in response to DCA-mediated stress. FEBS J 2006; 273: 1930-47.
18. Little TJ, Nelson L, Hupp T. Adaptive evolution of a stress response protein. PLoS ONE 2007; 2: e1003.
19. Yagui-Beltran A, Craig AL, Lawrie L, et al. The human oesophageal squamous epithelium exhibits a novel type of heat shock protein response. Eur J Biochem 2001; 268: 5343-55.
20. Pohler E, Craig AL, Cotton J, et al. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 2004; 3: 534-47.
21. Aberger F, Weidinger G, Grunz H, Richter K. Anterior specification of embryonic ectoderm: the role of the Xenopus cement gland-specific gene XAG-2. Mech Dev 1998; 72: 115-30.
22. Liu, D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005; 65: 3796-805.
23. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008; 68: 492-97.
24. Kumar A, Godwin JW, Gates PB, Garza-Garcia AA, Brockes JP. Molecular basis for the nerve dependence of limb regeneration in an adult vertebrate. Science 2007; 318: 772-77.
25. Zheng W, Rosenstiel P, Huse K, et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. Genes Immun 2006; 7: 11-18.
26. Zweitzig DR, Smirnov DA, Connelly MC, Terstappen LW, O'Hara SM, Moran E. Physiological stress induces the metastasis marker AGR2 in breast cancer cells. Mol Cell Biochem 2007; 306: 255-60
27. Mackay A, Urruticoechea A, Dixon JM, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007; 9: R37.
28. Zhang Y, Forootan SS, Liu D, et al. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007; 10: 293-300.
29. Murray E, McKenna EO, Burch LR, et al. CRUK Edinburgh Microarray-Formatted Clinical Biomarker Assay Development Using Peptide Aptamers to Anterior Gradient-2. Biochemistry 2007; 46: 13742-51.
30. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005; 43: 249-59.
31. Fletcher GC, Patel S, Tyson K, et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 2003; 88: 579-85.
32. Neduva V, Russell RB. Peptides mediating interaction networks: new leads at last. Curr Opin Biotechnol 2006; 17: 465-71.
33. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. Faseb J 2006; 20: 1599-610.
34. Dornan D, Hupp TR. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep 2001; 2: 139-144.
35. Dornan D, Eckert M, Wallace M, et al. Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol Cell Biol 2004; 24: 10083-98.
36. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004; 3: 419-21.
37. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008; 27: 5303-14.
38. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26: 3473-81.
39. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000; 2: 709-17
40. Galigniana MD, Harrell JM, O'Hagen HM, Ljungman M, Pratt WB. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem 2004; 279: 22483-89.
41. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64: 9152-59.
42. Aussedat B, Sagan S, Chassaing G, Bolbach G, Burlina F. Quantification of the efficiency of cargo delivery by peptidic and pseudopeptidic Trojan carriers using MALDI-TOF mass spectrometry. Biochim Biophys Acta 2006; 1758: 375-83.
43. Fischer PM, Zhelev NZ, Wang S, Melville JE, Fahraeus R, Lane DP. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J Pept Res 2000; 55: 163-72.
44. Zhu H, Lam DC, Han KC, et al. High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. Cancer Lett 2007; 245: 303-14.
45. Fritzsche FR, Dahl E, Dankof A, et al. Expression of AGR2 in non small cell lung cancer. Histol Histopathol 2007; 22: 703-08.
46. Missiaglia E, Blaveri E, Terris B, et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer 2004; 112: 100-12.
47. Neduva V, Russell RB. DILIMOT: discovery of linear motifs in proteins. Nucleic Acids Res 2006; 34: W350-355.
48. Neduva V, Linding R, Su-Angrand I, et al. Systematic discovery of new recognition peptides mediating protein interaction networks. PLoS Biol 2005; 3: e405.
49. Neduva V, Russell RB. Linear motifs: evolutionary interaction switches. FEBS Lett 2005; 579: 3342-45.
50. Linding R, Jensen LJ, Ostheimer GJ, et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007; 129: 1415-26.
51. Neduva V, Russell RB. Proline-rich regions in transcriptional complexes: heading in many directions. Sci STKE 2007; 2007(369): pe1.
52. Dornan D, Shimizu H, Burch L, Smith AJ, Hupp TR. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol Cell Biol 2003; 23: 8846-61.
53. Kontopidis G, Andrews MJ, McInnes C, et al. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (Camb) 2003; 11: 1537-46.
54. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102-9.
55. Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005; 7: 457-68.
56. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-93.
57. Burch LR, Scott M, Pohler E, Meek D, Hupp, T. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1. J Mol Biol 2004; 337: 115-28.
58. Burch L, Shimizu H, Smith A, Patterson C, Hupp TR. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein. J Mol Biol 2004; 337: 129-45.
59. Harrison B, Kraus M, Burch L, et al. DAPK-1 Binding to a Linear Peptide Motif in MAP1B Stimulates Autophagy and Membrane Blebbing. J Biol Chem 2008; 283: 9999-10014.
60. Zhang G, Gurtu V, Kain SR. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem Biophys Res Commun 1996; 227: 707-711.
61. Stevens C, Lin, Y, Burch L, et al. Peptide Combinatorial Libraries Identify TSC2 as a DAPK Death Domain Binding Protein and Reveal a Stimulatory Role for DAPK in mTORC1 Signalling. J Biol Chem 2008; [Epub ahead of press].